INBX vs PFE · rev $1.3M vs P/E 20, rev $15.03B
Inhibrx Biosciences, Inc. (INBX) versus Pfizer Inc (PFE) — a side-by-side from cached financials, not a winner call.
Inhibrx Biosciences, Inc. (INBX) is a biotechnology company listed on US.
Pfizer Inc (PFE) is a drug manufacturers - general company listed on NYSE. It is led by Albert Bourla.
Latest reported INBX revenue for 2025-12-31 was $1.3M. Net income was -$140.1M. Revenue was up 550.0% from 2024-12-31 to 2025-12-31. INBX currently screens at market cap $1.28B.
Latest reported PFE revenue for 2026-06-28 was $15.03B. Net income was -$248.0M. Revenue was up 4.0% from 2026-03-29 to 2026-06-28. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
INBX currently screens at market cap $1.28B. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
Not investment advice. Open the INBX and PFE stock pages for the full models.
Not investment advice.